These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35249050)

  • 1. [Ⅲ. Recent Trends in Chemotherapy, Targeted Therapy and Immunotherapy for Cervical Cancer and Promising New Treatments].
    Miwa M; Hasegawa K
    Gan To Kagaku Ryoho; 2022 Feb; 49(2):155-160. PubMed ID: 35249050
    [No Abstract]   [Full Text] [Related]  

  • 2. Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer.
    Crafton SM; Salani R
    Clin Ther; 2016 Mar; 38(3):449-58. PubMed ID: 26926322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and potential treatments for cervical cancer.
    Yee GP; de Souza P; Khachigian LM
    Curr Cancer Drug Targets; 2013 Feb; 13(2):205-20. PubMed ID: 23259831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in Cervical Cancer.
    Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
    Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Targeted therapy in locally and metastatic recurrent cervical cancers].
    Geiss R; De La Motte Rouge T; Dubot C; Leary A; Lhommé C; Pautier P; Scholl S; Rodrigues MJ
    Bull Cancer; 2014; 101(7-8):748-55. PubMed ID: 25091657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Agents in Cervical Cancer: Beyond Bevacizumab.
    Marquina G; Manzano A; Casado A
    Curr Oncol Rep; 2018 Apr; 20(5):40. PubMed ID: 29611060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of metastatic cervical cancer: future directions involving targeted agents.
    Diaz-Padilla I; Monk BJ; Mackay HJ; Oaknin A
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):303-14. PubMed ID: 22883215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy and Systemic Therapy in Metastatic/Recurrent Endometrial and Cervical Cancers.
    Lima J; Ali Z; Banerjee S
    Clin Oncol (R Coll Radiol); 2021 Sep; 33(9):608-615. PubMed ID: 34312021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ⅲ.The Current Status and Future Perspective of Chemotherapy, Targeted Therapy and Immunotherapy for Cervical Cancer].
    Yabuno A; Hasegawa K
    Gan To Kagaku Ryoho; 2020 Feb; 47(2):242-246. PubMed ID: 32381956
    [No Abstract]   [Full Text] [Related]  

  • 10. Investigational drugs for the treatment of cervical cancer.
    Barra F; Lorusso D; Leone Roberti Maggiore U; Ditto A; Bogani G; Raspagliesi F; Ferrero S
    Expert Opin Investig Drugs; 2017 Apr; 26(4):389-402. PubMed ID: 28274154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy and targeted therapy for cervical cancer: an update.
    Menderes G; Black J; Schwab CL; Santin AD
    Expert Rev Anticancer Ther; 2016; 16(1):83-98. PubMed ID: 26568261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
    Eskander RN; Tewari KS
    Clin Ther; 2015 Jan; 37(1):20-38. PubMed ID: 25592089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic approaches in the treatment of node-positive cervical cancer patients based on molecular targets: a systematic review.
    Sniadecki M; Swierzko A; Dabkowski M; Orlowska-Volk M; Wycinka E; Klasa-Mazurkiewicz D; Milewska A; Poniewierza P; Liro M; Wydra D
    Ginekol Pol; 2019; 90(6):336-345. PubMed ID: 31276186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer.
    Jiang P; Wang L; Hou B; Zhu J; Zhou M; Jiang J; Wang L; Chen S; Zhu S; Chen J; Zhang L
    Theranostics; 2018; 8(13):3544-3558. PubMed ID: 30026865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapy in cervical cancer: 30 years in review.
    Liontos M; Kyriazoglou A; Dimitriadis I; Dimopoulos MA; Bamias A
    Crit Rev Oncol Hematol; 2019 May; 137():9-17. PubMed ID: 31014518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
    Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
    J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates in Cervical Cancer Treatment.
    Hill EK
    Clin Obstet Gynecol; 2020 Mar; 63(1):3-11. PubMed ID: 31815773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of recent clinical investigations into systemic therapy against cervical cancer: systematic analysis of trial details from Clinicaltrials.gov.
    Girma B; Makonnen E; Shibeshi W
    J Obstet Gynaecol; 2022 Jul; 42(5):793-801. PubMed ID: 34907843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer.
    Eskander RN; Tewari KS
    J Gynecol Oncol; 2014 Jul; 25(3):249-59. PubMed ID: 25045438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
    Kagabu M; Nagasawa T; Sato C; Fukagawa Y; Kawamura H; Tomabechi H; Takemoto S; Shoji T; Baba T
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.